* participants with known hypersensitivity to ivermectin * clinical diagnosis of severe renal and hepatic impairment. * pregnancy or breast feeding. * co-treatment with either strong cytochrome p-450 inducers including: rifampicin, carbamazepine and barbiturates or inhibitors: isoniazid, clofazimine that might potentially affected ivermectin disposition and clinical outcomes * co-morbidities including asthma * loa loa as assessed by travel history to angola, cameroon, chad, central african republic, congo, dr congo, equatorial guinea, ethiopia, gabon, nigeria and sudan in the last 4 years * persons clinically diagnosed with and receiving treatment for any diathesis and pud * active participation in another clinical trial

* participants with known hypersensitivity to ivermectin * clinical diagnosis of severe renal and hepatic impairment. * pregnancy or breast feeding. * co-treatment with either strong cytochrome p-450 inducers including: rifampicin, carbamazepine and barbiturates or inhibitors: isoniazid, clofazimine that might potentially affected ivermectin disposition and clinical outcomes * co-morbidities including asthma * loa loa as assessed by travel history to angola, cameroon, chad, central african republic, congo, dr congo, equatorial guinea, ethiopia, gabon, nigeria and sudan in the last 4 years * persons clinically diagnosed with and receiving treatment for any diathesis and pud * active participation in another clinical trial

- participants with known hypersensitivity to ivermectin - clinical diagnosis of severe renal and hepatic impairment. - pregnancy or breast feeding. - co-treatment with either strong cytochrome p-450 inducers including: rifampicin, carbamazepine and barbiturates or inhibitors: isoniazid, clofazimine that might potentially affected ivermectin disposition and clinical outcomes - co-morbidities including asthma - loa loa as assessed by travel history to angola, cameroon, chad, central african republic, congo, dr congo, equatorial guinea, ethiopia, gabon, nigeria and sudan in the last 4 years - persons clinically diagnosed with and receiving treatment for any diathesis and pud - active participation in another clinical trial

- participants with known hypersensitivity to ivermectin - clinical diagnosis of severe renal and hepatic impairment. - pregnancy or breast feeding. - co-treatment with either strong cytochrome p-450 inducers including: rifampicin, carbamazepine and barbiturates or inhibitors: isoniazid, clofazimine that might potentially affected ivermectin disposition and clinical outcomes - co-morbidities including asthma - loa loa as assessed by travel history to angola, cameroon, chad, central african republic, congo, dr congo, equatorial guinea, ethiopia, gabon, nigeria and sudan in the last 4 years - persons clinically diagnosed with and receiving treatment for any diathesis and pud - active participation in another clinical trial